(WASHINGTON, D.C.) – The Pharmaceutical Care Management Association (PCMA) strongly supports legislation being considered today by the Senate Committee on Health, Education, Labor, and Pensions (HELP) as much-needed steps toward ending Big Pharma’s War on Generics that keeps patients paying high drug prices for too long.

PCMA supports:

• S. 1954, Biosimilar Red Tape Elimination Act: Eliminates the separate FDA “interchangeable” biosimilar designation and treats approved biosimilars as interchangeable under applicable state substitution laws.
• S. 2658, Medication Affordability and Patent Integrity Act: Seeks to curb pharmaceutical patent statements made to delay generic drug approval and their entry into the market.
• S. 3014, Ensuring Timely Access to Generics Act of 2025: Discourages the misuse of FDA citizen petitions intended to delay generic drug approval and market entry.

Ahead of the Committee markup, David Marin, President and CEO of PCMA, issued the following statement:

“We applaud the Committee for focusing on these bills because we know the only proven way to lower drug costs is by increasing competition. The three bills aimed at expanding access to lower-cost drugs represent a critical salvo against Big Pharma’s war on generics.

“We have a system in place that should work. Brand name drugs get a set amount of exclusivity on the market and when that expires, generics enter and costs fall. But it’s not working. Drug companies are abusing our patent system, making their expensive brand-name drugs the only option for patients for too long.

“The Committee’s action today should mark Congress’ first step toward enacting meaningful policy to lower drug costs. More generics and biosimilars will equate to lower drug costs. It’s that simple.”